Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wave 5 that was funny man really that was a good one dumpty time.
Needs to retest the 6's junior
$NERV
I don't even pay attention to these low level stocks Amateur hour time.
what ever you don't know charts go off an run away son.
Going to the low 6's technical analysis 101
$NERV
technical analysis on a quarter penny lol lmao
OK lol lmao
$NERV
Timber RSI 72 learn technical analysis son.
$NERV
hehehehe LMAO wave 4-5 NO WRONG! humpty dumpty time.
$NERV
Bleeding cash they did a reverse split a few months ago look for offerings bloat the float and then do another reverse split that's how the game works son.
$NERV
Ichimoku Base Line nuff said
Nah this thing is toast. Meme stock joke. Chart says its going back down to the 6's at least.
$NERV
Wave 4 is finished 17 people in the study. This thing is about to tank. RSI way out of wack.
-- Interim Phase 1/2 results for zilovertamab plus ibrutinib in MCL presented at ASCO 2022, with ORR of 85% compare favorably to historical single agent ibrutinib data and support moving into Phase 3 Study ZILO-301
-- Interim data from p53-mutated CLL patients in the same Phase 1/2 study showed encouraging activity in sub-group analyses, with landmark PFS of 100% at 36 months, compares favorably to historical PFS for ibrutinib monotherapy
-- Established a clinical trial and supply agreement with Pharmacyclics for the donation of ibrutinib for our global registrational Phase 3 study, ZILO-301, of zilovertamab in patients with MCL, which is on track to be initiated in September 2022
-- Advanced development of ONCT-808, the lead candidate for our autologous CAR-T program targeting ROR1-expressing malignancies, with IND submission on track for later this month
-- Executing IND enabling studies for ONCT-534, the lead candidate in our novel dual-action androgen receptor inhibitor (DAARI) program
-- Extended cash runway guidance to fund operations into the first half of 2024 with $78.9 million in cash and cash equivalents and no debt as of June 30, 2022
ONCT pipeline is showing more promising data than VelsoBio & NBE Therapeutics here is the key & the valuation of where ONCT should be. Abbive wants this pipeline & will make a take over offer sooner than later. The team at ONCT is top notch sesoned vets from some of the top biotech companies in the world. Their Pedigree is next level.
If you take a formula of three buyouts in the last year and change 2.8 Billion Merck on Velsobio & Boehringer Buyout of NBE-Therapeutics for 1.5 Billion & Trillium 2.2 Billion bought by Pfizer Onct is worth north of Billion. Their pipeline is more mature and their top line data is superior. Onct market cap of 67 Million has 20 to 30x ROI potential from these levels.
Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC
https://www.fiercebiotech.com › biotech › merck-inks-...
Merck has struck a deal to buy VelosBio for $2.75 billion. The takeover will give Merck control of an antibody-drug conjugate (ADC) that caused objective ...
You've visited this page 5 times. Last visit: 8/21/22
Boehringer inks $1.5B NBE buyout, joining Merck in new ...
https://www.fiercebiotech.com › biotech › boehringer-i...
Boehringer Ingelheim has struck a deal to buy NBE-Therapeutics for €1.2 billion ($1.5 billion) to add a ROR1-directed antibody-drug conjugate
Oncternal therapeutics: Zilovertamab Phase 3 study Ror1 ZILO-301 Kills cancer stem cells. HUGE Improvement Partnered with AbbV better approach then trillium which was bought out by Pfizer for 2.2 Billion for Hematological malignancies cancers. Next we had the 2 ROR1 buyouts last year and half. This stock is about to quantum leap. Under the radar hidden gem. Billion dollar plus market cap in the making. Onct is helping Imbruvica (PCYC) which as bought out by ABBV 21 Billion and has 9 Billion plus in sales. Zilovertamab in combo with Imbruvica is 50% more affective then Imbruvica alone with less side effects. Plus 9 indications in the ONCT pipeline including Prostate & Breast cancer Her2 (39 Billion market for Her2 Breast cancer in 2025 Onct market cap at 65 Million is extremely undervalued. The chart is turning around. Ror1 first in class in the making.
https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc
This is the most undervalued asset, 'explosive' move coming.
64k on the bid.
Lots of catalysts & hammers about to drop this company is extremely undervalued.
$ONCT
Oncternal therapeutics: Zilovertamab Phase 3 study Ror1 ZILO-301 Kills cancer stem cells. HUGE Improvement Partnered with AbbV better approach then trillium which was bought out by Pfizer for 2.2 Billion for Hematological malignancies cancers. Next we had the 2 ROR1 buyouts last year and half. This stock is about to quantum leap. Under the radar hidden gem. Billion dollar plus market cap in the making. Onct is helping Imbruvica (PCYC) which as bought out by ABBV 21 Billion and has 9 Billion plus in sales. Zilovertamab in combo with Imbruvica is 50% more affective then Imbruvica alone with less side effects. Plus 9 indications in the ONCT pipeline including Prostate & Breast cancer Her2 (39 Billion market for Her2 Breast cancer in 2025 Onct market cap at 65 Million is extremely undervalued. The chart is turning around. Ror1 first in class in the making.
https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc
This is the most undervalued asset, 'explosive' move coming.
Analyst update for ONCT
After Oncternal reported interim results from its ongoing Phase 1/2 CIRLL Study that Northland analyst Carl Byress said enforce the potential for the combination of Zilovertamab plus Ibrutinib for treating relapsed/ refractory mantle cell lymphoma, he argued that the updated interim data for the combination should serve as a catalysts doe shares as they are clearly supporting the registrational Phase 3 studies intitiating in Q3 of this year. He also noted that relapsed/ refractory mantle cell lymphoma patients achieve progression free survival or PFS which he sees bodes well for Zilvertamab as a major breakthrough byrnes has an outperform rating and a $15.00 price target on Oncternal shares.
$ONCT
Phase 3 with ABBV that makes their blockbuster drug Ibrutinib formerly pcyc which was bought out by ABBV for 20 billion this drug does 9 Billion in sales annually 50% more effective with less side effects. With ONCT Zilovertamab
R/R MCL: Tumor Reduction and Progression-Free Survival
Zilovertamab + Ibrutinib Data Update at ASCO 2022
85% ORR and median PFS of 35.9 months
ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL
Merck snatched up ROR1 veslobio for 2.75 Billion I think they may try and Buy ONCT better acting drug partnered with ABBV ibrutinib the combo works 50% better than the drug alone. Pcyc ibrutinib now ABBV is going to do 9.5-10 Billion in sales next year. I think Merck might buy ONCT more data further along in trials very robust pipeline. ROR1 expression on many tumor types
• Potential safety and efficacy advantages
• MK-2140 ADC data at ASH 2021: no apparent off-
tumor, on-target ROR1 toxicities.
ROR1 Expressed on Multiple
Solid and Liquid Tumor's
MCL 95%
CLL 95%
Uterus 96%
Lymphoma 90%
Prostate 90%
Skin 89%
Insiders have been buying it up just broke the 50 day moving average. I think Merck might come in to add to there Ror1 portfolio.
https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race
$MRK
Building higher support level broke the 50 day moving average
Imo ONCT in negotiations with AbbVie
Deals take time
Data was excellent. Doubled CR of ibrutinib alone in MCL (ibrutinib ) close to 10 billion in sales annually
Data in P53 mutant CCL is game changing
AbbVie collaborated on trial design
Agreed to provide ~$5M per month in ibrutinib for P3 trial
Recent options awards contained clause in case of change in control
Insiders Buying at these levels.
https://www.oncternal.com/pipeline
In it to win it.
INND grabbed a 200k for a crap shoot. And added some Onct today broke the 50 day moving average. Ror1 cancer. plays an essential role in embryogenesis and is overexpressed in many types of malignant tumors. Studies have demonstrated that it plays an important role in oncogenesis by activating cell survival signaling events, particularly the non-canonical WNT signaling pathway.
$INND
Anticipated Pipeline Milestones
Zilovertamab
• MCL global registrational Phase 3 Study ZILO-301 initiation September 2022
• MCL & CLL clinical data update for ongoing Phase 2 4Q 2022
ONCT-808 ROR1 CAR-T cell therapy:
• B-Cell malignancies U.S. IND submission August 2022
ONCT-534
• Prostate cancer FDA pre-IND interaction 4Q 2022
$Onct
Oncternal Therapeutics Provides Business Update.
Interim Phase 1/2 results for zilovertamab plus ibrutinib in MCL presented at ASCO 2022, with ORR of 85% and CR rate of 41%, compare favorably to historical single agent ibrutinib data and support moving into Phase 3 Study ZILO-301
Interim data from p53-mutated CLL patients in the same Phase 1/2 study showed encouraging activity in sub-group analyses, with landmark PFS of 100% at 36 months, compares favorably to historical PFS for ibrutinib monotherapy.
Established a clinical trial and supply agreement with Pharmacyclics for the donation of ibrutinib for our global registrational Phase 3 study, ZILO-301, of zilovertamab in patients with MCL, which is on track to be initiated in September 2022.
Advanced development of ONCT-808, the lead candidate for our autologous CAR-T program targeting ROR1-expressing malignancies, with IND submission on track for later this month.
Executing IND enabling studies for ONCT-534, the lead candidate in our novel dual-action androgen receptor inhibitor (DAARI) program.
Extended cash runway guidance to fund operations into the first half of 2024 with $78.9 million in cash and cash equivalents and no debt as of June 30, 2022
Corporate Presentation, August 2022
https://investor.oncternal.com/static-files/f7628e1c-42c5-4c8a-8247-e910ad5555c4
Onct Pipeline
https://www.oncternal.com/pipeline
$ONCT
what a beast glad I loaded last week.
$ALT
Imbruvica (ibrutinib) Pharmacyclics (AbbVie) and Janssen (Johnson & Johnson)
2021 Sales $9,777,000,000.00
Data was excellent. Doubled CR of (ABBV) ibrutinib alone in MCL
Data in P53 mutant CCL is game changing
Let this sink in on how valuable this combo is $$$
Anything under $2.00 is a hell of a discount this can quadruple in price in a blink of an eye with a $60 million market cap. Smart money is accumulating for 10-20x gains next 24-36 months. ten 10 drugs in the pipeline this is a Billion dollar plus market cap in the making.
Opportunity for a take over is in the cards two ROR1 acquisitions Merck acquired early clinical data VelsoBio.. for $2.8 Billion & Boehringer buys NBE Therapeutics $1.5Billion ROR1 deal last year.
$ONCT
Imbruvica (ibrutinib) Pharmacyclics (AbbVie)
2021 Sales $9,777,000,000.00
Data was excellent. Doubled CR of (ABBV) ibrutinib alone in MCL
Data in P53 mutant CCL is game changing
ABBV Let this sink in on how valuable this combo is $$$ for ABBV
Two ROR1 acquisitions Merck acquired early clinical data VelsoBio.. for $2.8 Billion & Boehringer buys NBE Therapeutics $1.5Billion ROR1 deal last year.
$ONCT
Outperform rating. Analyst Oppenheimer Hartaj Singh has a $14.00 price target over 1000% upside
https://seekingalpha.com/news/3679856-oppenheimer-sees-around-62-rise-in-shares-of-oncternal-therapuetics
ZILO-301: Phase III study of zilovertamab + ibrutinib Abbie blockbuster drug they bought from pharmacyclics for 21 Billion dollars in R/R MCL
Added again this one looks ready to go. New 52 week high in 2023
Great informant video of ABBV & ONCT combos in the clinic (cancer stem cells)
Oncternal Therapeutics Drives Complete Responders with First in Class ROR1 Antagonist The combo with ABBV looks off the charts. Big huge improvements with the combo treatment. 2 distinct drugs in the clinic with ABBV
10 drugs in the pipeline
081 - Oncternal Therapeutics Drives Complete Responders with First in Class ROR1 Antagonist
slapped the ask here a little. Let's go, Just closed an hourly over the 50 day moving average. Lots of catalysts as this deep oncology pipeline of 10 drugs moves forward with a Phase 3 commencing soon. One of only a few ROR1 assets in the clinic with outstanding data Merck bought one. & so
Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC.
https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc
Boehringer inks $1.5B NBE buyout, joining Merck in new ROR1 cancer race.
https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race
Oncternal Therapeutics Jumps on Bullish Oppenheimer Initiation
Oncternal was initiated with an outperform rating and a $14 price target. ... Oncternal Therapeutics (ONCT) -
HC Wainwright Sees This Small-Cap Biotech As Undervalued, Underappreciated
At the European Hematology Association (EHA) meeting, Oncternal Therapeutics Inc (NASDAQ: ONCT) presented initial preclinical results of Oncternal's ROR1 CAR containing the antigen-binding region of zilovertamab.
ONCT Pipeline.
https://www.oncternal.com/pipeline
$ONCT
ABBV 2 trials one with ibrutinib & the other zilovertamab with Oncternal Therapeutics ROR1 molecule the data speaks for itself. This is going to be huge for ABBV bottom line.
ABBV with Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022 Phase 3 starts in a few weeks in ths usa.
May 26, 2022 at 5:15 PM EDT
Updated MCL and CLL data from the CIRLL study are encouraging and continue to improve
ORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27 evaluable patients) for patients with MCL treated with zilovertamab plus ibrutinib compare favorably to historical ORR of 66% and CR of 20% for ibrutinib monotherapy
Data from p53-mutated MCL and CLL patients show encouraging response rates in sub-group analyses. Landmark PFS was over 80% at 15 months for MCL and 100% at 36 months for CLL in p53-mutated patients treated with zilovertamab plus ibrutinib
The combination of zilovertamab and ibrutinib continued to be well tolerated, with an adverse event profile consistent or improved compared with historical data for ibrutinib monotherapy.
ONCT is going to help ABBV with ibrutinib sales & with investigator-initiated studies, including a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL, and in a Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).
I think ABBV buys ONCT sooner than later 10 drugs in their pipeline.
ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL
(VIDEO 2 min)
VIDEO ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL
VIDEO ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL
10x-20x Potential in the cards DD
2 Buyouts of ROR1 Antibodies in the last year and half Merck 2.8 Billion &
Boehringer inks $1.5B NBE buyout. ROR1-directed antibody-drug .
ONCT 60 Million market cap Phase 3 starting with Abbie & deep diverse cutting edge pipeline. Tutes & Insiders own 40%+ of the 50 Million outstanding shares
79 million cash into 2024 lots of updates coming Q3 & $ Chart looks ripe for a massive reversal.
$ONCT
Took a starter here.
$ONCT
ZILOVERTAMAB: MONOCLONAL ANTIBODY TARGETING ROR1
ROR1 TARGETED CELL THERAPY PROGRAM
ONCT-534: DUAL-ACTION ANDROGEN RECEPTOR INHIBITOR (DAARI)
85% ORR and median survival of 35.9 months.
ONCT ROR1 expressed on multiple & liquid tumors.
MCL 95%
CLL 95%
Uterus 96%
Lymphoma 90%
Prostate 90%
Skin 89%
Pancreatic 83%
Adrenal 83%
Lung 77%
Breast 75%
Testicular 73%
2 companies in the last 2 years that targets ROR1 have been Merck bought VelosBio for 2.8 Billion & Boehringer inks $1.5B NBE buyout, joining Merck in new cancer ROR1 race. ONCT Market cap is under 60 Million.
Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC.
https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc
Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race.
https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race
Clinical Stage Biotech Focused on Hematological Malignancies and
Prostate Cancer with Multiple Modalities and Deep ROR1 Expertise
Hematological Malignancies Prostate Cancer
Zilovertamab – ROR1 monoclonal antibody
• Demonstrated clinical benefit of
combination with ibrutinib compared to
historical ibrutinib monotherapy, including
in difficult-to-treat p53 mutations
• Expect MCL registrational study initiation
in 3Q 2022
ONCT-808 – ROR1 CAR-T Cell Therapy
• Expect IND submission in August 2022
ONCT-534 – Dual Action AR Inhibitor (DAARI)
• First-in-class MOA interacting with both N-
terminal Domain and Ligand-Binding
Domain of the androgen receptor inducing
AR protein degradation
• Active preclinically in AR amplification, splice
variant and LBD mutation models
Zilovertamab – ROR1 monoclonal antibody
• Ph1b study open for advanced prostate cancer
-----------------------------------------------------------------------------------------------------------------
Corporate Highlights
ZILOVERTAMAB: POTENTIALLY FIRST-IN-CLASS MONOCLONAL ANTIBODY TARGETING ROR1
• Safety and efficacy results for zilovertamab + ibrutinib (ABBIE) (PCYC) in patients with MCL/CLL compare favorably to historical single-
agent ibrutinib
• Encouraging efficacy results in patients with p53 mutated CLL, with PFS of 100% at 24 and 30 months
• Agreement with U.S. FDA on Phase 3 global registrational study design for the treatment of patients with R/R MCL
ONCT-808: AUTOLOGOUS CAR-T CELL THERAPY TARGETING ROR1
• Clinical manufacturing agreement with the Dana-Farber Cancer Institute for first-in-human studies
• Research collaborations for next-gen allogeneic CAR-T and CAR-NK cell therapies with Karolinska Institutet & Celularity
ONCT-534: DUAL-ACTION ANDROGEN RECEPTOR INHIBITOR (DAARI)
• Activity in preclinical prostate cancer models of androgen receptor inhibitor resistance, including AR mutations, AR
overexpression and AR splice variants, such as AR-V7
MULTIPLE CATALYSTS
• Planned initiation of zilovertamab + ibrutinib global registrational Phase 3 Study ZILO-301 in 3Q 2022
• Clinical data updates in MCL and CLL
• ONCT-808 ROR1 CAR-T cell therapy IND submission planned in mid-2022
---------------------------------------------------------
Anticipated Pipeline Milestones
Zilovertamab
• MCL global registrational Phase 3 Study ZILO-301 initiation September 2022
• MCL & CLL clinical data update for ongoing Phase 2 4Q 2022
ONCT-808 ROR1 CAR-T cell therapy
• B-Cell malignancies U.S. IND submission August 2022
ONCT-534
• Prostate cancer FDA pre-IND interaction 4Q 2022
Cash & Cash Investments
Cash Runway well into 1H 2024
$78.9M
Debt $0M
ONCT Team Includes Veterans from Fate therapeutics, Merck, Pfizer, Gilead, Amgen, Johnson & Johnson, Roche, Lilly, & Takeda.
August 2022 ONCT Biz presentation.
https://investor.oncternal.com/static-files/f7628e1c-42c5-4c8a-8247-e910ad5555c4
ONCT Pipeline.
https://www.oncternal.com/pipeline
Will add more on closing after the 50 day moving average which is right there 1.165
& add again after we break the 200 day moving average. $1.81
About 50 million shares outstanding.
% Held by Institutions 31%
% Held by Insiders 11%
Insiders have been buying.
$ONCT